Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Adimab Announces New Antibody Discovery Collaboration with Celgene

Published: Thursday, August 22, 2013
Last Updated: Thursday, August 22, 2013
Bookmark and Share
Adimab will use its proprietary platform to generate therapeutic antibodies against multiple targets.

Adimab, LLC has announced a multi-target discovery collaboration with Celgene Corporation of Summit, NJ. Under terms of the Agreement, Adimab will use its proprietary platform to generate therapeutic antibodies against multiple targets.

Celgene will have the right to develop and commercialize all therapeutic antibodies resulting from the collaboration.

“We are very pleased to announce another major pharma partnership,” said Tillman Gerngross, CEO and co-founder of Adimab.

Gerngross continued, “Celgene has developed a highly successful oncology and inflammation franchise, and we are excited to partner with them to support their expanding antibody-based therapeutic portfolio.”

Adimab and Celgene have entered into a collaboration whereby Adimab will use its proprietary discovery and optimization platform to identify fully human antibodies against multiple targets.

For each target, the agreement grants Celgene the right to research antibodies generated during the collaboration for potential use as therapeutic products.

Under the terms of the Agreement, Adimab will receive an undisclosed upfront payment. In addition, for each target, Celgene will have the option to exclusively license antibodies
generated during the collaboration.

If Celgene exercises its option for a particular target, Adimab would receive license fees, clinical milestones and royalties on therapeutic product sales.

“The speed and technical superiority of our platform drives all of our deal flow,” said Guy Van Meter, Vice President of Business Development at Adimab. “The Adimab Platform is an extremely versatile antibody discovery and engineering tool that can be applied to a variety of different therapeutic development approaches, including IgG discovery, optimization, humanization, and bispecifics.”

Over the past four years, Adimab has established collaborations with multiple leading pharmaceutical companies, including Merck, Roche, Novartis, Eli Lilly, Genentech, Biogen Idec, Novo Nordisk, Gilead, Kyowa Hakko Kirin and GSK.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Adimab and Mersana Announce Antibody-Drug Conjugate Alliance
Partners to offer integrated antibody discovery and ADC capabilities.
Tuesday, August 14, 2012
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Gene Regulation in Brain May Explain Repetitive Behaviors in Rett Syndrome Patients
The research could be a key step in developing treatments to eliminate symptoms that drastically impair the quality of life in Rett patients.
Atmosphere Acidity Minimised to Preindustrial Levels
Sheet ice study shows acidic pollution of the atmosphere has now almost returned to preindustrial levels.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Culex Mosquitoes Do Not Transmit Zika
A study of the Culex species mosquito appears to show that the species does not transmit Zika virus.
Uncovering Water Bear Resilience
A protein identified in water bears can protect DNA of human cells from lethal doses of radiation damage.
“Sixth Sense” More Than a Feeling
NIH study of rare genetic disorder reveals importance of touch and body awareness.
Researchers Find Fungus-Fighting Compound
A compound has been identifed that blocks growth of a fungus responsible for lung infections and allergic reactions.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!